What Was Eli Lilly Telling You Before Its Stock Ran?
Yahoo · 17 de oct de 2026
An investor who put $10,000 into Eli Lilly (LLY) stock on October 14, 2025 held about $15,500 by October 15, 2026. Placing that same sum in the S&P 500 over the…
CEDEAR LLY
Eli Lilly and Company
Sí, existe CEDEAR de LLY en Argentina. Operás bajo el ticker LLY en BYMA, con ratio 56:1 respecto a la acción en NYSE.
Empresa subyacente
HealthcareDrug Manufacturers - General
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
- País
- United States
- Empleados
- 50.000
- Sitio web
- lilly.com
Precio histórico
Últimos 225 días · 12/11/25 — 15/10/26
+35.51%
Cotización y datos
NYSERatio 56:1 · Subyacente LLY
CEDEAR (ARS)
Precio
$ 36.320
Var. %
+0,39%
Volumen operado
24.200
Subyacente (USD)
Precio LLY
US$ 1.258,43
Teórico (precio / ratio)
LLY ÷ 56
US$ 22,47
Dólar MEP (LLYD)
Preguntas frecuentes
¿Existe CEDEAR de LLY en Argentina?
Sí, existe el CEDEAR de LLY (Eli Lilly and Company) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es LLY.
¿Cuál es el ticker del CEDEAR de Eli Lilly and Company?
El ticker del CEDEAR de Eli Lilly and Company en Argentina es LLY. La acción subyacente cotiza en NYSE con el símbolo LLY.
¿Cuál es el ratio del CEDEAR LLY?
El CEDEAR LLY tiene un ratio de 56:1. Eso significa que 56 CEDEARs equivalen a 1 acción de LLY.
¿Cuánto vale el CEDEAR LLY hoy?
El CEDEAR LLY cotiza hoy a $ 36.320 en pesos argentinos, con una variación diaria de +0,39%.
¿Cuánto vale la acción LLY en dólares?
Noticias
3 Great Biotech Stocks To Watch In October 2026
Yahoo · 17 de oct de 2026
High energy costs are pushing inflation concerns back into focus after crude oil moved above US$100, and that kind of pressure often pushes investors toward hig…
Moderna Stock Slumps, but It’s Too Early to Panic
Yahoo · 16 de oct de 2026
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.